Abstract
A randomized, double-blind, placebo-controlled trial assessed the therapeutic efficacy of intranasal pirodavir in naturally occurring rhinovirus colds. Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times daily for 5 days. In people with laboratory-documented rhinovirus colds (53 in the pirodavir group, 55 in the placebo group), no significant differences in the resolution of respiratory symptoms were apparent between the groups. The median duration of illness was 7 days in each group. Similarly, scores for individual symptoms found no differences in favor of pirodavir during or after treatment. In contrast, reduced frequencies of rhinovirus shedding were observed in the pirodavir group on day 3 (70 versus 23%; P < 0.001) and day 5 (38 versus 12%; P = 0.002) but not after the cessation of treatment, on day 7 (19 versus 21%). No pirodavir-resistant viruses were recovered from treated individuals. The pirodavir group had higher rates of nasal dryness, blood in mucus, or unpleasant taste on several study days. In summary, intranasal sprays of pirodavir were associated with significant antiviral effects but no clinical benefit in treating naturally occurring rhinovirus colds.
Full Text
The Full Text of this article is available as a PDF (216.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andries K., Dewindt B., Snoeks J., Willebrords R., van Eemeren K., Stokbroekx R., Janssen P. A. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100–107. doi: 10.1128/aac.36.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dearden C., al-Nakib W., Andries K., Woestenborghs R., Tyrrell D. A. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol. 1989;109(1-2):71–81. doi: 10.1007/BF01310519. [DOI] [PubMed] [Google Scholar]
- Hayden F. G., Andries K., Janssen P. A. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992 Apr;36(4):727–732. doi: 10.1128/aac.36.4.727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayden F. G., Kaiser D. L., Albrecht J. K. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother. 1988 Feb;32(2):224–230. doi: 10.1128/aac.32.2.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McBride T. P., Doyle W. J., Hayden F. G., Gwaltney J. M., Jr Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection. Arch Otolaryngol Head Neck Surg. 1989 Sep;115(9):1054–1059. doi: 10.1001/archotol.1989.01860330044014. [DOI] [PubMed] [Google Scholar]
- Sperber S. J., Hayden F. G. Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother. 1988 Apr;32(4):409–419. doi: 10.1128/aac.32.4.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- al-Nakib W., Higgins P. G., Barrow G. I., Tyrrell D. A., Andries K., Vanden Bussche G., Taylor N., Janssen P. A. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 1989 Apr;33(4):522–525. doi: 10.1128/aac.33.4.522. [DOI] [PMC free article] [PubMed] [Google Scholar]